Yaniv Shaya - Imperva President
President
Mr. Yaniv Shaya is Senior Vice President Engineering of Imperva Ltd. an Israeli subsidiary of Imperva Inc. since July 2012. From August 2009 to July 2012 he served as the Vice President Engineering of Imperva Ltd. Prior to that from April 2005 to August 2009 Mr. Shaya was a Director of Research and Development for Mercury Interactive Corporationration an IT management software and services company since 2012.
| Age | 42 |
| Tenure | 12 years |
| Professional Marks | MBA |
| Phone | 650 345-9004 |
| Web | www.imperva.com |
Imperva Management Efficiency
The company has return on total asset (ROA) of 0.0474 % which means that it generated a profit of $0.0474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0812 %, meaning that it created $0.0812 on every $100 dollars invested by stockholders. Imperva's management efficiency ratios could be used to measure how well Imperva manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 621.95 K in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Imperva has a current ratio of 2.0, which is within standard range for the sector. Debt can assist Imperva until it has trouble settling it off, either with new capital or with free cash flow. So, Imperva's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Imperva sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Imperva to invest in growth at high rates of return. When we think about Imperva's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 14 records | PRESIDENT Age | ||
| Sheila Brockman | SunLink Health Systems | 64 | |
| Jason Gottlieb | Artisan Partners Asset | 54 | |
| Amy Rock | Cumberland Pharmaceuticals | N/A | |
| Yuichi Tsujimoto | HUTCHMED DRC | 60 | |
| Sarah Johnson | Artisan Partners Asset | 52 | |
| Eileen Kwei | Artisan Partners Asset | 45 | |
| James Hamman | Artisan Partners Asset | 54 | |
| Hiroshi Tokushige | HUTCHMED DRC | 64 | |
| Byron Finn | SunLink Health Systems | 68 | |
| Morio Sumiya | HUTCHMED DRC | 55 | |
| Koji Sumioka | HUTCHMED DRC | 59 | |
| Leo Pavliv | Cumberland Pharmaceuticals | 54 | |
| Tadashi Motoi | HUTCHMED DRC | 56 | |
| Dean Patenaude | Artisan Partners Asset | 52 | |
Management Performance
| Return On Equity | 0.0812 | |||
| Return On Asset | 0.0474 |
Imperva Leadership Team
Elected by the shareholders, the Imperva's board of directors comprises two types of representatives: Imperva inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Imperva. The board's role is to monitor Imperva's management team and ensure that shareholders' interests are well served. Imperva's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Imperva's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Giancarlo, Director | ||
| Tram Phi, Senior Vice President General Counsel, Corporate Secretary | ||
| Randall Spratt, Director | ||
| Christopher Hylen, President CEO, Director | ||
| David Gee, Chief Marketing Officer | ||
| Theresia Ranzetta, Independent Director | ||
| Terrence Schmid, CFO, Principal Accounting Officer and Treasurer | ||
| Mark Kraynak, Sr. VP and General Manager of The Enterprise Solutions Group | ||
| Michael Mooney, Chief Revenue Officer | ||
| Meg Bear, Senior Vice President - Cloud Services | ||
| Amichai Shulman, Co-Founder, CTO and CTO of Imperva LTD | ||
| Anthony Bettencourt, CEO and President and Director | ||
| Mary Bear, Senior Vice President - Cloud Services | ||
| Allan Tessler, Director | ||
| Mike Burns, CFO | ||
| Frank Slootman, Independent Director | ||
| Brett Hooper, Senior Vice President - People | ||
| David Woodcock, Senior Vice President of Worldwide Sales | ||
| Terry Ray, CTO | ||
| Kim DeCarlis, Chief Marketing Officer | ||
| Albert Pimentel, Independent Director | ||
| Aaron Kuan, Interim CFO | ||
| Roger Sippl, Director | ||
| Yaniv Shaya, Senior Vice President - Engineering of Imperva, Ltd. | ||
| Sunil Nagdev, Senior Vice President Worldwide Services and Suppor | ||
| James Tolonen, Director | ||
| Geraldine Elliott, Director |
Imperva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Imperva a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0812 | |||
| Return On Asset | 0.0474 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | (2.24) % | |||
| Current Valuation | 1.65 B | |||
| Shares Outstanding | 35.44 M | |||
| Shares Owned By Insiders | 1.17 % | |||
| Shares Owned By Institutions | 98.83 % | |||
| Number Of Shares Shorted | 1.68 M | |||
| Price To Earning | 73.13 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Imperva Stock
If you are still planning to invest in Imperva check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Imperva's history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |